Breadcrumb Home Studies Studies Search Filter Research Area AllBrain and Mental HealthCure and ImmunotherapyTherapeuticsTuberculosis Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentOpen to AccrualParticipants Off Study and Primary Analysis CompletedWithdrawn Sort Study Number AscStudy Number Desc Submit Search Showing 7 studies. IMPAACT 2051: Phase II Study of the Pharmacokinetics, Safety, Tolerability, and Anti-Mycobacterial Activity of Pretomanid with Bedaquiline, Linezolid, with or without Moxifloxacin (BPaL/M) in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 39258 Research Area Tuberculosis Study Status In Development IMPAACT 2048/HVTN 145: Phase I Study of the Safety and Pharmacokinetics of VRC07-523LS, ePGT121v1-LS, and PDGM1400LS Alone and in Combination in Breastfeeding Infants DAIDS Number TBD Research Area Treatment Study Status In Development IMPAACT 2047: Radiant-Moms Plus DAIDS Number 39188 Research Area Tuberculosis Study Status In Development IMPAACT 2044: Phase IV Study of the Pharmacokinetics and Safety of Ceftriaxone and Benzathine Penicillin G During Pregnancy DAIDS Number 39132 Research Area Therapeutics Study Status Enrolling IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Enrolling IMPAACT 2020: Phase II Study of Shortened Oral Treatment for Rifampicin-Resistant Tuberculosis in Children DAIDS Number 38505 Research Area Tuberculosis Study Status Withdrawn IMPAACT 2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) in Children with MDR-TB with and without HIV DAIDS Number 20721 Research Area Tuberculosis Study Status Closed to Follow Up
IMPAACT 2051: Phase II Study of the Pharmacokinetics, Safety, Tolerability, and Anti-Mycobacterial Activity of Pretomanid with Bedaquiline, Linezolid, with or without Moxifloxacin (BPaL/M) in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 39258 Research Area Tuberculosis Study Status In Development
IMPAACT 2048/HVTN 145: Phase I Study of the Safety and Pharmacokinetics of VRC07-523LS, ePGT121v1-LS, and PDGM1400LS Alone and in Combination in Breastfeeding Infants DAIDS Number TBD Research Area Treatment Study Status In Development
IMPAACT 2047: Radiant-Moms Plus DAIDS Number 39188 Research Area Tuberculosis Study Status In Development
IMPAACT 2044: Phase IV Study of the Pharmacokinetics and Safety of Ceftriaxone and Benzathine Penicillin G During Pregnancy DAIDS Number 39132 Research Area Therapeutics Study Status Enrolling
IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Enrolling
IMPAACT 2020: Phase II Study of Shortened Oral Treatment for Rifampicin-Resistant Tuberculosis in Children DAIDS Number 38505 Research Area Tuberculosis Study Status Withdrawn
IMPAACT 2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) in Children with MDR-TB with and without HIV DAIDS Number 20721 Research Area Tuberculosis Study Status Closed to Follow Up
